Angiogenesis, Metabolism, Endothelial and Platelet Markers in Diabetes and Cardiovascular Disease.

IF 4.6 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY British Journal of Biomedical Science Pub Date : 2022-03-22 eCollection Date: 2022-01-01 DOI:10.3389/bjbs.2022.10313
A D Blann, J E Brown, R Heitmar
{"title":"Angiogenesis, Metabolism, Endothelial and Platelet Markers in Diabetes and Cardiovascular Disease.","authors":"A D Blann,&nbsp;J E Brown,&nbsp;R Heitmar","doi":"10.3389/bjbs.2022.10313","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction:</b> Diabetes is a leading risk factor for cardiovascular disease (CVD), the pathophysiology of both being linked to metabolic, endothelial, renal, angiogenic and platelet abnormalities. We hypothesised that abnormalities in these systems are more adverse in those whose CVD is compounded by diabetes, compared to those with diabetes or CVD alone. <b>Materials and methods:</b> Serum or plasma from 66 patients with diabetes alone, 76 with CVD alone, and 70 with both diabetes and CVD i.e. diabetic cardiovascular disease, was probed for markers of angiogenesis [angiopoietin 1 and 2, vascular endothelial growth factor (VEGF) and endoglin], metabolic [soluble receptor for advanced glycation products (sRAGE), leptin, lipocalin-2, interleukin-8, and cystatin-C], the endothelium (von Willebrand factor, endothelial microparticles and soluble E selectin)], and the platelet (platelet microparticles and soluble P selectin) by ELISA, Luminex or flow cytometry. <b>Results:</b> VEGF (<i>p</i> = 0.04), von Willebrand factor (<i>p</i> = 0.001) and endothelial microparticles (<i>p</i> = 0.042) were all higher in diabetic cardiovascular disease than in diabetes alone and cardiovascular disease alone. Soluble E selectin was higher in diabetic cardiovascular disease than in diabetes alone (<i>p</i> = 0.045), whilst cystatin-C (<i>p</i> = 0.004) and soluble P selectin (<i>p</i> < 0.001) were higher in diabetes and diabetic cardiovascular disease than in cardiovascular disease alone. There were no differences in angiopoietin 1 or 2, endoglin, sRAGE, leptin, lipocalin-2, or interleukin-8. <b>Conclusion:</b> Angiopoietin 1 or 2, endoglin, sRAGE, leptin, lipocalin-2, interleukin-8, and cystatin-c cannot differentiate diabetes from cardiovascular disease, or both conditions combined. Our data point to a more adverse endothelial (von Willebrand factor, endothelial microparticles), and angiogenic profile (VEGF) in those with diabetic cardiovascular disease, supporting the view that this group should be targeted more aggressively.</p>","PeriodicalId":9236,"journal":{"name":"British Journal of Biomedical Science","volume":" ","pages":"10313"},"PeriodicalIF":4.6000,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302542/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Biomedical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/bjbs.2022.10313","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

Introduction: Diabetes is a leading risk factor for cardiovascular disease (CVD), the pathophysiology of both being linked to metabolic, endothelial, renal, angiogenic and platelet abnormalities. We hypothesised that abnormalities in these systems are more adverse in those whose CVD is compounded by diabetes, compared to those with diabetes or CVD alone. Materials and methods: Serum or plasma from 66 patients with diabetes alone, 76 with CVD alone, and 70 with both diabetes and CVD i.e. diabetic cardiovascular disease, was probed for markers of angiogenesis [angiopoietin 1 and 2, vascular endothelial growth factor (VEGF) and endoglin], metabolic [soluble receptor for advanced glycation products (sRAGE), leptin, lipocalin-2, interleukin-8, and cystatin-C], the endothelium (von Willebrand factor, endothelial microparticles and soluble E selectin)], and the platelet (platelet microparticles and soluble P selectin) by ELISA, Luminex or flow cytometry. Results: VEGF (p = 0.04), von Willebrand factor (p = 0.001) and endothelial microparticles (p = 0.042) were all higher in diabetic cardiovascular disease than in diabetes alone and cardiovascular disease alone. Soluble E selectin was higher in diabetic cardiovascular disease than in diabetes alone (p = 0.045), whilst cystatin-C (p = 0.004) and soluble P selectin (p < 0.001) were higher in diabetes and diabetic cardiovascular disease than in cardiovascular disease alone. There were no differences in angiopoietin 1 or 2, endoglin, sRAGE, leptin, lipocalin-2, or interleukin-8. Conclusion: Angiopoietin 1 or 2, endoglin, sRAGE, leptin, lipocalin-2, interleukin-8, and cystatin-c cannot differentiate diabetes from cardiovascular disease, or both conditions combined. Our data point to a more adverse endothelial (von Willebrand factor, endothelial microparticles), and angiogenic profile (VEGF) in those with diabetic cardiovascular disease, supporting the view that this group should be targeted more aggressively.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
糖尿病和心血管疾病中的血管生成、代谢、内皮和血小板标志物。
糖尿病是心血管疾病(CVD)的主要危险因素,两者的病理生理学都与代谢、内皮、肾脏、血管生成和血小板异常有关。我们假设CVD合并糖尿病患者的这些系统异常比糖尿病或CVD患者更不利。材料和方法:对66例单纯性糖尿病患者、76例单纯性CVD患者和70例糖尿病合并CVD患者(即糖尿病性心血管疾病患者)的血清或血浆进行血管生成[血管生成素1和2、血管内皮生长因子(VEGF)和内皮素]、代谢[晚期糖基化产物可溶性受体(sRAGE)、瘦素、脂钙素-2、白介素-8和胱抑素- c]、内皮(血管性血血病因子、内皮微粒和可溶性E选择素)]标志物检测。ELISA、Luminex或流式细胞术检测血小板(血小板微粒和可溶性P选择素)。结果:糖尿病心血管病患者的VEGF (p = 0.04)、血管性血血病因子(p = 0.001)和内皮微粒(p = 0.042)均高于糖尿病和心血管病患者。可溶性E选择素在糖尿病心血管疾病中的含量高于单独的糖尿病(p = 0.045),而胱他汀- c (p = 0.004)和可溶性p选择素在糖尿病和糖尿病心血管疾病中的含量高于单独的心血管疾病(p < 0.001)。血管生成素1或2、内啡肽、sRAGE、瘦素、脂钙素-2或白细胞介素-8没有差异。结论:血管生成素1或2、内激素、sRAGE、瘦素、脂钙素-2、白介素-8和胱抑素-c不能区分糖尿病与心血管疾病,或两者合并。我们的数据表明,糖尿病心血管疾病患者的内皮(血管性血血病因子,内皮微粒)和血管生成谱(VEGF)更不利,支持这一群体应该更积极地靶向治疗的观点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
British Journal of Biomedical Science
British Journal of Biomedical Science 医学-医学实验技术
CiteScore
4.40
自引率
15.80%
发文量
29
审稿时长
>12 weeks
期刊介绍: The British Journal of Biomedical Science is committed to publishing high quality original research that represents a clear advance in the practice of biomedical science, and reviews that summarise recent advances in the field of biomedical science. The overall aim of the Journal is to provide a platform for the dissemination of new and innovative information on the diagnosis and management of disease that is valuable to the practicing laboratory scientist.
期刊最新文献
An Analysis of the Readability of Public-Facing Information Relating to Prevention of Infectious Diseases by Vaccination. Molecular Effects of Glucose on MIR503HG-Regulated Genes in Triple-Negative Breast Cancer. Epidemiological Analysis of Antinuclear Antibodies Positivity and Pattern Distribution in a Taiwanese Hospital-Based Cohort. Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities. Influence of Reference Gene Selection on miRNA Quantification by RT-qPCR in Human Placental Samples.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1